Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
Citius Pharmaceuticals (CTXR) Stock Price & Analysis
1,169 Followers
CTXR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.63 - $1.71
Previous Close$0.69
Volume359.80K
Average Volume (3M)1.16M
Market Cap
$109.91M
Enterprise ValueN/A
Total Cash (Recent Filing)$33.28M
Total Debt (Recent Filing)$532.88K
Price to Earnings (P/E)-3.3
Beta1.24
Next Earnings
Dec 13, 2023EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding158,857,798
10 Day Avg. Volume644,226
30 Day Avg. Volume1,158,139
Standard Deviation0.30
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$4.00Price Target Upside484.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Citius Pharmaceuticals News
Pre-EarningsCitius Pharma (CTXR) Q3 Earnings Cheat Sheet
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTXR FAQ
What was Citius Pharmaceuticals’s price range in the past 12 months?
Citius Pharmaceuticals lowest stock price was $0.63 and its highest was $1.71 in the past 12 months.
What is Citius Pharmaceuticals’s market cap?
Currently, no data Available
When is Citius Pharmaceuticals’s upcoming earnings report date?
Citius Pharmaceuticals’s upcoming earnings report date is Dec 13, 2023 which is in 74 days.
How were Citius Pharmaceuticals’s earnings last quarter?
Citius Pharmaceuticals released its earnings results on Aug 14, 2023. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Citius Pharmaceuticals overvalued?
According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued.
Does Citius Pharmaceuticals pay dividends?
Citius Pharmaceuticals does not currently pay dividends.
What is Citius Pharmaceuticals’s EPS estimate?
Citius Pharmaceuticals’s EPS estimate is -$0.04.
How many shares outstanding does Citius Pharmaceuticals have?
Citius Pharmaceuticals has 158,857,800 shares outstanding.
What happened to Citius Pharmaceuticals’s price movement after its last earnings report?
Citius Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Citius Pharmaceuticals?
Among the largest hedge funds holding Citius Pharmaceuticals’s share is Gotham Asset Management LLC. It holds Citius Pharmaceuticals’s shares valued at N/A.
---
Citius Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (484.45% Upside)
$4.00 (484.45% Upside)
Blogger Sentiment
Neutral
CTXR Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.89%
12-Months-Change
Fundamentals
Return on Equity
-29.49%
Trailing 12-Months
Asset Growth
-8.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
---
Top 5 ETFs holding CTXR
Vanguard Total Stock Market ETF
$3.77M
Vanguard Russell 3000 ETF
$6.98K
Up to five ETFs with an Outperform Smart Score that hold CTXR. The ETFs are listed according to market value of CTXR within the ETF
---